Review article · 2025 · Open access
T cell engagers: expanding horizons in oncology and beyond
British Journal of Cancer, 133(9), 1241–1249 · Published 23 July 2025 · DOI 10.1038/s41416-025-03125-y
In brief
“T cell engagers: expanding horizons in oncology and beyond” is a 2025 review article by Gülşah Albayrak and 3 co-authors, published in British Journal of Cancer. OpenAlex counts 95 citations as of 18 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at British Journal of Cancer.
- Citations
- 95
- Most cited in
- 2026 (86)
- Field-weighted impact
- 9.12
- References
- 88
- Authors
- 4
Abstract
BACKGROUND/INTRODUCTION: T cell engagers (TCEs) are engineered immunotherapeutic molecules designed to direct the body's immune system against tumour or infected cells by bridging T cells and their targets, triggering potent cytotoxic responses. Over the past decade, TCE-based therapies have gained momentum in oncology, resulting in several FDA approvals for haematologic malignancies and showing growing promise in solid tumours. OBJECTIVE: This review elaborates on TCE mechanisms of action, emphasising their ability to activate T cells, target tumour antigens, and modulate the tumour microenvironment. METHODS/RESULTS: We also delve into the clinical outcomes demonstrating TCE efficacy, alongside challenges such as cytokine release syndrome, antigen heterogeneity, and short half-lives. Recent advances in TCE design have incorporated multispecific constructs and conditional activation strategies and expansion in target molecules has enabled broadening applications to non-oncology indications like autoimmune and infectious diseases. Moreover, the use of artificial intelligence (AI) has also accelerated TCE discovery by identifying favourable epitope interactions, reducing immunogenicity risks, and enhancing overall design efficiency. CONCLUSIONS: Looking further, these advances open up a new era to redefine success for TCEs in both cancer and beyond, offering hope for more effective, safer immunotherapies.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Albayrak, G., Wan, P. K.-T., Fisher, K. D., & Seymour, L. W. (2025). T cell engagers: expanding horizons in oncology and beyond. British Journal of Cancer, 133(9), 1241–1249. https://doi.org/10.1038/s41416-025-03125-y
MLA 9
Albayrak, Gülşah, et al. “T cell engagers: expanding horizons in oncology and beyond.” British Journal of Cancer, vol. 133, no. 9, 2025, pp. 1241–1249. https://doi.org/10.1038/s41416-025-03125-y.
Chicago
Albayrak, Gülşah, Peter Kok-Ting Wan, Kerry D. Fisher, and Leonard William Seymour. 2025. “T cell engagers: expanding horizons in oncology and beyond.” British Journal of Cancer 133 (9): 1241–1249. https://doi.org/10.1038/s41416-025-03125-y.
Harvard
Albayrak, G. et al. (2025) ‘T cell engagers: expanding horizons in oncology and beyond’, British Journal of Cancer, 133(9), pp. 1241–1249. doi:10.1038/s41416-025-03125-y.
IEEE
G. Albayrak, P. K.-T. Wan, K. D. Fisher, and L. W. Seymour, “T cell engagers: expanding horizons in oncology and beyond,” British Journal of Cancer, vol. 133, no. 9, pp. 1241–1249, 2025, doi: 10.1038/s41416-025-03125-y.
BibTeX
@article{albayrak2025cell,
title = {{T cell engagers: expanding horizons in oncology and beyond}},
author = {Albayrak, Gülşah and Wan, Peter Kok-Ting and Fisher, Kerry D. and Seymour, Leonard William},
journal = {British Journal of Cancer},
year = {2025},
volume = {133},
number = {9},
pages = {1241--1249},
doi = {10.1038/s41416-025-03125-y},
url = {https://doi.org/10.1038/s41416-025-03125-y}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- T-cell engagers
- bispecific T-cell engagers
- T cell activation
- tumor antigens
- tumor microenvironment
- hematologic malignancies
- solid tumors
- cytokine release syndrome
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Albayrak, G., Wan, P. K.-T., Fisher, K. D., & Seymour, L. W. (2025). T cell engagers: expanding horizons in oncology and beyond. British Journal of Cancer, 133(9), 1241–1249. https://doi.org/10.1038/s41416-025-03125-y
How many times has this paper been cited?
95 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at British Journal of Cancer: sign in and open the PDF from this page.
Who wrote this paper?
Gülşah Albayrak, Peter Kok-Ting Wan, Kerry D. Fisher, Leonard William Seymour.
What is the DOI of this paper?
10.1038/s41416-025-03125-y, permanently at https://doi.org/10.1038/s41416-025-03125-y. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.